Yousif Capital Management LLC Has $21.05 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Yousif Capital Management LLC cut its stake in Amgen Inc. (NASDAQ:AMGN) by 1.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 73,070 shares of the medical research company’s stock after selling 1,136 shares during the period. Yousif Capital Management LLC’s holdings in Amgen were worth $21,046,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of AMGN. Briaud Financial Planning Inc bought a new stake in Amgen during the third quarter worth about $26,000. BOK Financial Private Wealth Inc. acquired a new stake in Amgen during the 4th quarter valued at $29,000. OFI Invest Asset Management bought a new position in Amgen in the 3rd quarter valued at $26,000. Planned Solutions Inc. bought a new position in Amgen in the 4th quarter valued at $30,000. Finally, Providence Capital Advisors LLC acquired a new position in Amgen in the third quarter worth $30,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on AMGN shares. Oppenheimer reiterated an “outperform” rating and set a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. Raymond James started coverage on shares of Amgen in a research note on Thursday, March 28th. They set a “market perform” rating on the stock. SVB Leerink cut shares of Amgen from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $324.00 to $318.00 in a research report on Wednesday, February 7th. Royal Bank of Canada reissued an “outperform” rating and set a $329.00 price objective on shares of Amgen in a report on Wednesday, April 3rd. Finally, TD Cowen lowered their price target on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Ten research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Stock Up 0.6 %

AMGN stock traded up $1.63 during mid-day trading on Tuesday, hitting $273.54. 2,493,074 shares of the company were exchanged, compared to its average volume of 2,845,341. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The firm’s 50 day simple moving average is $276.11 and its 200 day simple moving average is $281.61. The firm has a market cap of $146.72 billion, a P/E ratio of 21.90, a P/E/G ratio of 2.50 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s revenue was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.09 earnings per share. On average, sell-side analysts predict that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.29%. Amgen’s dividend payout ratio is currently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.